Statement by FDA Commissioner Scott Gottlieb on new steps by FDA to advance patient engagement in the agency’s regulatory work

FDA

11 October 2017 - The FDA is hosting a pioneering event today: the first meeting of the Patient Engagement Advisory Committee or PEAC. 

It’s a significant step forward in the FDA’s efforts to broaden its engagement with patients – and to deepen the involvement of patients in our regulatory activities.

This is the agency’s first advisory committee that’s comprised solely of patients, care-partners, and those who represent their needs. Founded by the FDA’s Center for Devices and Radiological Health (CDRH), it reflects CDRH’s commitment to keep patients at the center of their work.

The FDA’s work requires us to establish objective, consistent criteria on which we base our decisions. But ultimately, the criteria we use to judge benefit and risk turn on the parameters that matter to patients.

Read FDA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , Patient , Engagement